<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02347072</url>
  </required_header>
  <id_info>
    <org_study_id>PT003011-00</org_study_id>
    <nct_id>NCT02347072</nct_id>
  </id_info>
  <brief_title>24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo</brief_title>
  <official_title>A Randomized, Phase IIIb, Three-period, Three-treatment, Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects With Moderate to Very Severe COPD After 4 Weeks of Treatment With PT003, Open-Label Spiriva® Respimat® (Tiotropium Bromide) as an Active Control, and Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, Phase IIIb, Three-period, Three-treatment, Double-blind, Multi-center, Crossover
      Study to Evaluate the 24-hour Lung Function Profile in Subjects with Moderate to Very Severe
      COPD after 4 Weeks of Treatment with PT003, Open-Label Spiriva® Respimat® (Tiotropium
      Bromide) as an Active Control, and Placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2015</start_date>
  <completion_date type="Actual">March 1, 2016</completion_date>
  <primary_completion_date type="Actual">August 1, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) 0-24</measure>
    <time_frame>Pre dose, 15 and 30 minutes, 1, 2, 4, 8, 12, 12.25, 12.5, 13, 14, 16, 22, and 24 hours post the morning dose on Day 29</time_frame>
    <description>Normalized Forced Expiratory Volume in 1 second (FEV1) Area Under the Curve (AUC) 0-24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC12-24</measure>
    <time_frame>Pre dose, 15 and 30 minutes, 1, 2, 4, 8, and 12 hours post the evening dose on Day 29</time_frame>
    <description>Normalized FEV1 AUC12-24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-12</measure>
    <time_frame>Pre dose, 15 and 30 minutes, 1, 2, 4, 8, and 12 hours post the morning dose on Day 29</time_frame>
    <description>Normalized FEV1 AUC0-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in FEV1 Evening</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>Peak Change From Baseline in FEV1 Evening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in FEV1 Morning</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>Peak Change From Baseline in FEV1 Morning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Pre-Dose Trough FEV1 on Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>Morning Pre-Dose Trough FEV1 on Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Pre-Dose Trough FEV1 on Day 30</measure>
    <time_frame>Day 30</time_frame>
    <description>Morning Pre-Dose Trough FEV1 on Day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in IC (Inspiratory Capacity) Evening</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>Peak Change From Baseline in IC Evening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in IC Morning</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>Peak Change From Baseline in IC Morning</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>GFF MDI (PT003)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MDI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spiriva® Respimat® (Tiotropium Bromide)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFF MDI (PT003)</intervention_name>
    <arm_group_label>GFF MDI (PT003)</arm_group_label>
    <other_name>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo MDI</intervention_name>
    <arm_group_label>Placebo MDI</arm_group_label>
    <other_name>Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spiriva® Respimat® (Tiotropium Bromide)</intervention_name>
    <description>Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)</description>
    <arm_group_label>Spiriva® Respimat® (Tiotropium Bromide)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 40 years of age and no older than 80 at Screening

          -  Women of non-child bearing potential or negative serum pregnancy test at Screening,
             and agrees to acceptable contraceptive methods used consistently and correctly
             Screening until 14 days after final visit.

          -  Subjects with an established clinical history of COPD as defined by the American
             Thoracic Society (ATS)/European Respiratory Society (ERS)

          -  Current or former smokers with a history of at least 10 pack-years of cigarette
             smoking

          -  Pre- and post-bronchodilator FEV1/FVC ratio of &lt;0.70

          -  Post-bronchodilator FEV1 must be &lt;80% predicted normal value, calculated using NHANES
             III reference equations, and the measured FEV1 must also be ≥750 mL if FEV1 &lt;30% of
             predicted normal value.

        Exclusion Criteria:

          -  Significant diseases other than COPD, i.e., disease or condition which, in the opinion
             of the Investigator, may put the subject at risk because of participation in the study
             or may influence either the results of the study or the subject's ability to
             participate in the study.

          -  Women who are pregnant or lactating.

          -  Subjects, who in the opinion of the Investigator, have a current diagnosis of asthma.

          -  Subjects who have been hospitalized due to poorly controlled COPD within 3 months
             prior to Screening or during the Screening Period.

          -  Subjects who have poorly controlled COPD, defined as acute worsening of COPD that
             requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to
             Screening or during the Screening Period.

          -  Subjects who have clinically significant uncontrolled hypertension.

          -  Subjects who have cancer that has not been in complete remission for at least five
             years.

          -  Subjects with abnormal liver function tests defined as AST, ALT, or total bilirubin
             ≥1.5 times upper limit of normal at Screening and on repeat testing.

          -  Subjects with a diagnosis of angle closure glaucoma will be excluded, regardless of
             whether or not they have been treated. Subjects with a diagnosis of open angle
             glaucoma who have intraocular pressure controlled with medication(s) are eligible.

          -  Subjects with symptomatic prostatic hypertrophy that is clinically significant in the
             opinion of the Investigator. Subjects with a trans-urethral resection of prostate
             (TURP) or full resection of the prostate within 6 months prior to Screening are
             excluded from the study.

          -  Subjects with bladder neck obstruction or urinary retention that is clinically
             significant in the opinion of the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pearl Therapeutics</affiliation>
  </overall_official>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2015</study_first_submitted>
  <study_first_submitted_qc>January 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2015</study_first_posted>
  <results_first_submitted>August 19, 2016</results_first_submitted>
  <results_first_submitted_qc>March 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2017</results_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 10 sites in the US from February 2015 to August 2015. The study was anticipated to run for approximately 9 months but not expected to exceed 12 months.</recruitment_details>
      <pre_assignment_details>Study to assess the efficacy and safety of GFF MDI 14.4/9.6µg relative to either Placebo MDI or Spiriva Respimat 5µg. Subjects were randomized into 1 of 6 treatment sequences, and all treatment sequences included all 3 treatments. By-treatment sequence tabulations of the data were not pre-specified.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>All Subjects Randomized</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GFF MDI 14.4/9.6 µg</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo MDI</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Spiriva Respimat 5 µg</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disc due to Protocol-specified Criteria</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>MITT population was a subset of the ITT Population including subjects who received treatment and had post treatment efficacy data from at least 2 treatment periods and this population is used for baseline characteristics. Participant Flow includes all patients randomized, regardless of treatment received.</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.8" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) 0-24</title>
        <description>Normalized Forced Expiratory Volume in 1 second (FEV1) Area Under the Curve (AUC) 0-24</description>
        <time_frame>Pre dose, 15 and 30 minutes, 1, 2, 4, 8, 12, 12.25, 12.5, 13, 14, 16, 22, and 24 hours post the morning dose on Day 29</time_frame>
        <population>Subjects in the Modified Intent to Treat (MITT) Population who had a sufficient number of post dose FEV1 measurements</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI</title>
            <description>Glycopyrronium Formoterol GFF Metered Dose Inhaler MDI 14.4/9.6µg</description>
          </group>
          <group group_id="O2">
            <title>Spiriva Respimat</title>
            <description>Spiriva Respimat 5μg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) 0-24</title>
          <description>Normalized Forced Expiratory Volume in 1 second (FEV1) Area Under the Curve (AUC) 0-24</description>
          <population>Subjects in the Modified Intent to Treat (MITT) Population who had a sufficient number of post dose FEV1 measurements</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.192" lower_limit="0.141" upper_limit="0.243"/>
                    <measurement group_id="O2" value="0.112" lower_limit="0.061" upper_limit="0.162"/>
                    <measurement group_id="O3" value="-0.072" lower_limit="-0.123" upper_limit="-0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC12-24</title>
        <description>Normalized FEV1 AUC12-24</description>
        <time_frame>Pre dose, 15 and 30 minutes, 1, 2, 4, 8, and 12 hours post the evening dose on Day 29</time_frame>
        <population>Subjects in the MITT Population who had a sufficient number of post dose FEV1 measurements</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI</title>
            <description>Glycopyrronium Formoterol GFF Metered Dose Inhaler MDI 14.4/9.6µg</description>
          </group>
          <group group_id="O2">
            <title>Spiriva Respimat</title>
            <description>Spiriva Respimat 5μg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC12-24</title>
          <description>Normalized FEV1 AUC12-24</description>
          <population>Subjects in the MITT Population who had a sufficient number of post dose FEV1 measurements</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.159" lower_limit="0.104" upper_limit="0.214"/>
                    <measurement group_id="O2" value="0.039" lower_limit="-0.015" upper_limit="0.094"/>
                    <measurement group_id="O3" value="-0.118" lower_limit="-0.173" upper_limit="-0.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC0-12</title>
        <description>Normalized FEV1 AUC0-12</description>
        <time_frame>Pre dose, 15 and 30 minutes, 1, 2, 4, 8, and 12 hours post the morning dose on Day 29</time_frame>
        <population>Subjects in the MITT Population who had a sufficient number of post dose FEV1 measurements</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI</title>
            <description>Glycopyrronium Formoterol GFF Metered Dose Inhaler MDI 14.4/9.6µg</description>
          </group>
          <group group_id="O2">
            <title>Spiriva Respimat</title>
            <description>Spiriva Respimat 5μg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC0-12</title>
          <description>Normalized FEV1 AUC0-12</description>
          <population>Subjects in the MITT Population who had a sufficient number of post dose FEV1 measurements</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.226" lower_limit="0.175" upper_limit="0.276"/>
                    <measurement group_id="O2" value="0.178" lower_limit="0.127" upper_limit="0.228"/>
                    <measurement group_id="O3" value="-0.026" lower_limit="-0.077" upper_limit="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in FEV1 Evening</title>
        <description>Peak Change From Baseline in FEV1 Evening</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI</title>
            <description>Glycopyrronium Formoterol GFF Metered Dose Inhaler MDI 14.4/9.6µg</description>
          </group>
          <group group_id="O2">
            <title>Spiriva Respimat</title>
            <description>Spiriva Respimat 5μg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1 Evening</title>
          <description>Peak Change From Baseline in FEV1 Evening</description>
          <population>MITT Population</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.395" lower_limit="0.334" upper_limit="0.456"/>
                    <measurement group_id="O2" value="0.230" lower_limit="0.170" upper_limit="0.291"/>
                    <measurement group_id="O3" value="0.058" lower_limit="-0.003" upper_limit="0.119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in FEV1 Morning</title>
        <description>Peak Change From Baseline in FEV1 Morning</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>Subjects in the MITT Population who had a sufficient number of post dose FEV1 measurements</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI</title>
            <description>Glycopyrronium Formoterol GFF Metered Dose Inhaler MDI 14.4/9.6µg</description>
          </group>
          <group group_id="O2">
            <title>Spiriva Respimat</title>
            <description>Spiriva Respimat 5μg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1 Morning</title>
          <description>Peak Change From Baseline in FEV1 Morning</description>
          <population>Subjects in the MITT Population who had a sufficient number of post dose FEV1 measurements</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.406" lower_limit="0.351" upper_limit="0.462"/>
                    <measurement group_id="O2" value="0.325" lower_limit="0.270" upper_limit="0.381"/>
                    <measurement group_id="O3" value="0.129" lower_limit="0.073" upper_limit="0.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Pre-Dose Trough FEV1 on Day 29</title>
        <description>Morning Pre-Dose Trough FEV1 on Day 29</description>
        <time_frame>Day 29</time_frame>
        <population>Subjects in the MITT Population who had a sufficient number of post dose FEV1 measurements</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI</title>
            <description>Glycopyrronium Formoterol GFF Metered Dose Inhaler MDI 14.4/9.6µg</description>
          </group>
          <group group_id="O2">
            <title>Spiriva Respimat</title>
            <description>Spiriva Respimat 5μg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Pre-Dose Trough FEV1 on Day 29</title>
          <description>Morning Pre-Dose Trough FEV1 on Day 29</description>
          <population>Subjects in the MITT Population who had a sufficient number of post dose FEV1 measurements</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.140" lower_limit="0.095" upper_limit="0.185"/>
                    <measurement group_id="O2" value="0.097" lower_limit="0.053" upper_limit="0.142"/>
                    <measurement group_id="O3" value="-0.020" lower_limit="-0.066" upper_limit="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Pre-Dose Trough FEV1 on Day 30</title>
        <description>Morning Pre-Dose Trough FEV1 on Day 30</description>
        <time_frame>Day 30</time_frame>
        <population>Subjects in the MITT Population who had a sufficient number of post dose FEV1 measurements</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI</title>
            <description>Glycopyrronium Formoterol GFF Metered Dose Inhaler MDI 14.4/9.6µg</description>
          </group>
          <group group_id="O2">
            <title>Spiriva Respimat</title>
            <description>Spiriva Respimat 5μg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Pre-Dose Trough FEV1 on Day 30</title>
          <description>Morning Pre-Dose Trough FEV1 on Day 30</description>
          <population>Subjects in the MITT Population who had a sufficient number of post dose FEV1 measurements</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.129" lower_limit="0.073" upper_limit="0.185"/>
                    <measurement group_id="O2" value="0.072" lower_limit="0.015" upper_limit="0.128"/>
                    <measurement group_id="O3" value="-0.073" lower_limit="-0.130" upper_limit="-0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in IC (Inspiratory Capacity) Evening</title>
        <description>Peak Change From Baseline in IC Evening</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>Subjects in the MITT Population who had a sufficient number of post dose FEV1 measurements</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI</title>
            <description>Glycopyrronium Formoterol GFF Metered Dose Inhaler MDI 14.4/9.6µg</description>
          </group>
          <group group_id="O2">
            <title>Spiriva Respimat</title>
            <description>Spiriva Respimat 5μg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in IC (Inspiratory Capacity) Evening</title>
          <description>Peak Change From Baseline in IC Evening</description>
          <population>Subjects in the MITT Population who had a sufficient number of post dose FEV1 measurements</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.421" lower_limit="0.343" upper_limit="0.498"/>
                    <measurement group_id="O2" value="0.297" lower_limit="0.221" upper_limit="0.372"/>
                    <measurement group_id="O3" value="0.109" lower_limit="0.032" upper_limit="0.186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in IC Morning</title>
        <description>Peak Change From Baseline in IC Morning</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>Subjects in the MITT Population who had a sufficient number of post dose FEV1 measurements</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI</title>
            <description>Glycopyrronium Formoterol GFF Metered Dose Inhaler MDI 14.4/9.6µg</description>
          </group>
          <group group_id="O2">
            <title>Spiriva Respimat</title>
            <description>Spiriva Respimat 5μg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in IC Morning</title>
          <description>Peak Change From Baseline in IC Morning</description>
          <population>Subjects in the MITT Population who had a sufficient number of post dose FEV1 measurements</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.454" lower_limit="0.388" upper_limit="0.520"/>
                    <measurement group_id="O2" value="0.374" lower_limit="0.307" upper_limit="0.440"/>
                    <measurement group_id="O3" value="0.206" lower_limit="0.139" upper_limit="0.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time the subject signed consent up to the follow-up phone call 7-14 days after last dose of study drug.</time_frame>
      <desc>The Safety Population was defined as all subjects who were randomized to treatment and received at least one dose of study treatment. Serious adverse events collected from time of consent up to 14 days after last dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>GFF MDI</title>
          <description>Glycopyrronium Formoterol GFF Metered Dose Inhaler MDI 14.4/9.6µg</description>
        </group>
        <group group_id="E2">
          <title>Spiriva Respimat</title>
          <description>Spiriva Respimat 5μg</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo MDI</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Colin Reisner, MD, FCCP, FAAAAI</name_or_title>
      <organization>Pearl Therapeutics Inc.</organization>
      <phone>650-350-2600</phone>
      <email>creisner@pearltherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

